Business Context and Reporting Period
This Form 8-K was filed by Greatbatch, Inc. on January 10, 2014. The report details a strategic initiative to expand the company's product portfolio beyond components into complete medical device systems.
Key Event: CE Mark Application
On January 10, 2014, Greatbatch, Inc. submitted an application to TÜV SÜD America, a designated European Notified Body, for CE Mark approval of its Spinal Cord Stimulation System (SCS). This system is designed to treat chronic intractable pain of the trunk and/or limbs.
Strategic Rationale
The filing indicates a strategic evolution to develop complete medical device systems to enhance the company's growth and profitability profile. This initiative is facilitated through the subsidiary QiG Group and leverages Greatbatch's existing intellectual property and discrete technologies.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory filing event and strategic direction rather than financial performance data.
Material Changes
The primary material change is the initiation of the regulatory approval process for a new complete medical device system (SCS) in Europe, marking a shift in product strategy.
Outlook and Risks
Management commentary suggests that the new medical device strategy is intended to raise the growth and profitability profile of the Company. The filing does not explicitly list specific risks, contingencies, or unusual items associated with this event, though regulatory approval is inherently contingent.
Investor Verification Checklist
- Verify the status of the CE Mark application with TÜV SÜD America.
- Confirm the operational role and capabilities of the QiG Group subsidiary.
- Assess the timeline for potential market entry of the Spinal Cord Stimulation System in Europe.
- Review future filings for financial impact projections related to this new product line.